The all randomized/full analysis set (ICH E9) - May patients be excluded from the analysis?

Drug Information Journal

Volumn 35, Issue 3, 2001, Pages 881-891

  Lange, S ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Exclusions; Full analysis set; Intention to treat; Pragmatic approach; Randomization

Indexed keywords

CONFERENCE PAPER; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; SAFETY; STATISTICAL ANALYSIS;

EID: 0034847373     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150103500327     Document Type: Conference Paper

References (26)

1. Sulfinpyrazone in the prevention of sudden death after myocardial infarction
2. The FDA's critique of the anturane reinfarction trial
3. The qualification and disqualification of patients and events in long-term cardiovascular clinical trials
4. Controversy in counting and attributing events in clinical trials
5. Counting events in clinical trials
6. Eligibility exclusions, losses to follow up, removal of randomized patients, and uncounted events in cancer clinical trials
7. Intention to treat in clinical practice
8. The application of the principle of intention-to-treat to the analysis of clinical trials
9. Intention-to-treat analysis: Implications for quantitative and qualitative research
10. Intention to treat-who should use ITT?
11. Intent-to-treat analysis versus astreated analysis
12. Note for guidance III/3630/92-EN: Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
14. Exclusions, losses to follow-up, and withdrawals in clinical trials
15. Explanatory and pragmatic attitudes in therapeutical trials
16. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
17. Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection
18. Sparfloxacin vs. ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study
19. How many populations must be analyzed and how should they be defined (intention-to-treat, eligible, per protocol population, etc.)?
20. Minimisation: The platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does
21. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
22. Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac
23. 'Proving the Null Hypothesis' in Clinical Trials